Brief: Cocrystal Pharma Reports Favorable Prelim Data From Phase 1 Initial Cohorts With CC-42344
12/04/2022 13:14
April 12 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA REPORTS FAVORABLE PRELIMINARY DATA FROM
PHASE 1
INITIAL COHORTS WITH CC-42344, A NOVEL, BROAD-SPECTRUM INFLUENZA
A ANTIVIRAL
* COCRYSTAL - CC-42344 ADMINISTERED ORALLY AS A SINGLE 100
MG OR
200 MG DOSE IN HEALTHY ADULTS SHOWED A FAVORABLE SAFETY AND
PHARMACOKINETIC PROFILE
Source text for Eikon: ID:nGNX22RR9F
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway